Your browser doesn't support javascript.
COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.
Daamen, Andrea R; Bachali, Prathyusha; Bonham, Catherine A; Somerville, Lindsay; Sturek, Jeffrey M; Grammer, Amrie C; Kadl, Alexandra; Lipsky, Peter E.
  • Daamen AR; AMPEL BioSolutions LLC, Charlottesville, VA, United States.
  • Bachali P; AMPEL BioSolutions LLC, Charlottesville, VA, United States.
  • Bonham CA; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Charlottesville, VA, United States.
  • Somerville L; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Charlottesville, VA, United States.
  • Sturek JM; Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
  • Grammer AC; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Charlottesville, VA, United States.
  • Kadl A; AMPEL BioSolutions LLC, Charlottesville, VA, United States.
  • Lipsky PE; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Charlottesville, VA, United States.
Front Immunol ; 13: 989556, 2022.
Article in English | MEDLINE | ID: covidwho-2109766
ABSTRACT
COVID-19 manifests a spectrum of respiratory symptoms, with the more severe often requiring hospitalization. To identify markers for disease progression, we analyzed longitudinal gene expression data from patients with confirmed SARS-CoV-2 infection admitted to the intensive care unit (ICU) for acute hypoxic respiratory failure (AHRF) as well as other ICU patients with or without AHRF and correlated results of gene set enrichment analysis with clinical features. The results were then compared with a second dataset of COVID-19 patients separated by disease stage and severity. Transcriptomic analysis revealed that enrichment of plasma cells (PCs) was characteristic of all COVID-19 patients whereas enrichment of interferon (IFN) and neutrophil gene signatures was specific to patients requiring hospitalization. Furthermore, gene expression results were used to divide AHRF COVID-19 patients into 2 groups with differences in immune profiles and clinical features indicative of severe disease. Thus, transcriptomic analysis reveals gene signatures unique to COVID-19 patients and provides opportunities for identification of the most at-risk individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.989556

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.989556